ARDELYX INC. - COMMON

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

08 Nov 2024 12:31:21 By Nasdaq GlobeNewswire

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

05 Nov 2024 08:00:32 By Nasdaq GlobeNewswire

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

31 Oct 2024 16:02:40 By Nasdaq GlobeNewswire

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting

28 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

24 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

22 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community

21 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

17 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week

15 Oct 2024 08:00:20 By Nasdaq GlobeNewswire

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

09 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

01 Aug 2024 16:01:02 By Nasdaq GlobeNewswire

Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion

31 Jul 2024 08:02:00 By Nasdaq GlobeNewswire

Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

18 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines

17 Jul 2024 17:10:43 By Nasdaq GlobeNewswire

To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA

02 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines

28 Jun 2024 08:17:59 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

30 May 2024 16:02:00 By Nasdaq GlobeNewswire

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

22 May 2024 08:02:00 By Nasdaq GlobeNewswire